AstraZeneca Wins Rare Autoimmune Indication for Asthma Biologic Fasenra

With the FDA’s approval, Fasenra will compete with GSK’s Nucala, which in December 2017 became the first biologic approved for eosinophilic granulomatosis with polyangiitis.